Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $1,762,750.00 in Stock

by · The Markets Daily

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 11,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the transaction, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. The trade was a 29.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jude Onyia also recently made the following trade(s):

  • On Wednesday, May 27th, Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $155.53, for a total transaction of $1,710,830.00.

Neurocrine Biosciences Stock Down 3.8%

NBIX traded down $6.16 during trading on Tuesday, hitting $154.84. 1,039,465 shares of the company’s stock were exchanged, compared to its average volume of 1,177,157. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $162.39. The stock has a market cap of $15.57 billion, a P/E ratio of 23.86, a PEG ratio of 1.19 and a beta of 0.39. The business’s 50 day moving average is $139.98 and its two-hundred day moving average is $139.18.

Analysts Set New Price Targets

NBIX has been the subject of several recent analyst reports. Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. Morgan Stanley upped their target price on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. BMO Capital Markets reduced their target price on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. Wolfe Research initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price for the company. Finally, Leerink Partners upped their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $187.52.

Check Out Our Latest Stock Report on Neurocrine Biosciences

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors have recently added to or reduced their stakes in NBIX. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares during the period. Norges Bank bought a new position in Neurocrine Biosciences during the fourth quarter valued at about $162,664,000. UBS Group AG grew its position in Neurocrine Biosciences by 169.8% during the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after buying an additional 618,956 shares during the period. First Trust Advisors LP grew its position in Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after buying an additional 472,408 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock valued at $664,019,000 after buying an additional 468,405 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

See Also